Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
One of the biggest obstacles in successfully treating metabolic disorders such as diabetes, obesity, fatty liver etc, is the variation in the way patients respond to medication. The key to this variation lies in the inherent biological differences between individuals, which cannot all be explained genetically. At the same time, this variation makes it very difficult to develop “standard” treatments for certain diseases. In a groundbreaking initiative, EPFL and ETHZ scientists have developed a strategy that can define and explain metabolic differences between individuals, essentially paving the way for precision medicine. The work, which also highlights significant issues with animal-based drug studies, is published in Science.
We are increasingly learning that medical interventions can be more successful when they are tailored to the specific profile of the individual patient. The problem is that defining that profile is extremely difficult, as it involves information on the person’s genome, proteins, fats, and all sorts of other layers of biology that make up their tissues and body. And so far, the only differences that we have been seriously taking into account are those found between genes.
This is what the labs of Johan Auwerx at EPFL and Ruedi Aebersold at ETH Zurich set out to solve with their recently published study. Looking at 40 different mice strains, the researchers successfully connected the variation between individuals’ genomes to the variation between their proteomes — their full set of proteins. In this way, they took a giant leap in profiling the biology of a particular individual.
“There is a black box between a patient’s genome and their disease,” says Johan Auwerx, whose lab handled the genome side of the study. “What we have done here is find a way to fill the black box by obtaining information on the patient’s proteome.”
“It’s much more complex to measure the set of proteins than to sequence the entire genome,” says Yibo Wu, co-lead author of the study. The scientists used protein data from mice, which they obtained from a new mass spectrometry technique that Aebersold’s group developed, known as SWATH-MS. This is a technique that combines the advantages of high-throughput mass spectrometry with high reproducibility and consistency. In short, it is able to identify thousands of different proteins in hundreds of samples much faster and accurately than conventional techniques, allowing the researchers to measure the concentrations of a broad spectrum of liver proteins in the mice.
The researchers measured a total of 2,600 different proteins from tissue samples of 40 mice strains, all of which came from the same two ancestors, meaning that they were genetically related to each other. “We wanted to keep the genetics simple in order to observe differences in the impact of environment (diet) on the proteome, other layers of biology, and their predisposition to develop diseases,” says Auwerx.
The mice were divided into groups of representing each of the 40 strains, and the groups were fed either a high-fat diet – essentially junk food – or a healthy, low-fat diet. Over a few weeks, the scientists charted the mice’s physiological data, and tested how fast they could gain weight on the junk-food diet and lose weight by exercising. Despite their similar genetic make-up, the mice on the high-fat diet showed varied responses to diet and exercise. For example, some developed metabolic disorders like fatty liver, while others did not.
The researchers then combined the physiological data with data for their genome, their proteome, and their transcriptome, which is essentially their full set of RNAs — another biological “layer” in the black box. Through this combination, the scientists were able to better understand the role several proteins play when it comes to metabolizing fat and producing energy from it.
“Like the mouse strains in this study, each patient with a disease is genetically different”, says Ruedi Aebersold. “The approach we used in the mouse cohort can now be applied one-for-one in research on human diseases, and particularly for personalized medicine.” The SWATH-MS approach is now ready to use in human cohort studies, as the researchers in his group have produces a corresponding database for thousands of human proteins.
“The aim here is to be able to customise medical intervention for each patient based on their individual biological makeup, the ‘black box’,” says Auwerx. In this vein, his group is now looking at specific drugs that can be used more effectively with this approach to treat metabolic disorders.
Learn more: New tool brings personalized medicine closer
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Precision Medicine Market 2020 Business Opportunities for Manufacturers: Johnson & Johnson, IBM, GE Healthcare, Illumina, Rocheon July 14, 2020 at 10:20 am
According to the National Institutes of Health (NIH), precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, ...
- Sheba launches world's first ‘reversed personalized medicine’ cancer trialon July 9, 2020 at 10:15 am
A first-ever human clinical trial could extend or even save patients’ lives by neutralizing cancer’s ability to block a patient’s natural immune defense mechanisms, which are usually exhausted when ...
- The Future of Medicine Is Bespokeon July 3, 2020 at 8:05 am
During the last hundred years, modern medicine has undergone a sea change. Just think of it — an ever-expanding repertoire of medicines, high-tech procedures, therapies and reams of clinical data to ...
- Bioinformatics Services Market – Bioinformatics Services Finding Wide Application in Personalized Medicine Discoveryon June 29, 2020 at 3:04 am
Bioinformatics services is fundamental to precision medicine as developing personalized medicine depends on accessing genetic and molecular data. In recent years, the majority of the molecularly ...
- Assessing the Value of Personalized Treatment in mBCon June 24, 2020 at 10:28 am
Assessing the value of personalized medicine from a payer and provider perspective and the importance of evidence-based data. Assessing the value of personalized medicine from a payer and provider ...
- Why Personalized Medicine Has The Power And Potential To Extend Your Lifeon June 22, 2020 at 4:24 am
Well, longevity experts have revealed several factors that could help increase our longevity, and one of these elements is an advancement in technology, particularly personalized medicine.
- Personalized Medicine Market 2020 Worldwide Opportunities, Driving Forces, COVID-19 Impact Analysis, Future Potential 2028on June 21, 2020 at 11:08 pm
The above mentioned data is compiled using information from former editions of PMC's Case for Personalized Medicine (2008-2014) with 2016 data from FDA's Table of Pharmacogenomic Biomarkers in ...
- Global Personalized Medicine Market 2020-2025 - Current Technologies Propelling Market Growthon June 15, 2020 at 11:56 am
Disclaimer | Commerce Policy | Made In NYC | Stock quotes by finanzen.net DUBLIN, June 15, 2020 /PRNewswire/ -- The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to ...
- Global Personalized Medicine Market 2020-2025 - Current Technologies Propelling Market Growthon June 15, 2020 at 11:48 am
DUBLIN, June 15, 2020 /PRNewswire/ -- The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 - Strategic Analysis of Industry Trends, Technologies, Participants ...
via Bing News